EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis

Alexander Drilon iD, Byoung Chul Cho, D Ross Camidge, Misako Nagasaka iD, Benjamin Besse iD, Benjamin Solomon, Koichi Goto iD, Jürgen Wolf, Sanjay Popat iD, Enriqueta Felip, Nong Yang, Adrianus Johannes de Langen iD und 9 weitere

The Oncologist · 2026

DOI: 10.1093/oncolo/oyag137 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Oncologist, 2026. Verfasst von Alexander Drilon und 20 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, United States. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein Kinase Inhibitors, Pyrazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute/National Institutes of Health, Nonna's Garden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Repotrectinib, a next-generation ROS1/TRK tyrosine kinase inhibitor, is approved for ROS1 fusion-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. Its side effects and safety management strategies require further characterization. Patients and Methods The safety profile of repotrectinib (treatment-emergent/related adverse events [TEAEs/TRAEs]) was established in patients who initiated treatment at the recommended dose (160 mg daily [QD] for 14 days, then 160 mg twice daily [BID]) across all cohorts of the global, multicenter phase 1/2 TRIDENT-1 study. AE management strategies were outlined.

Results

In 472 patients, the most common TRAEs (dizziness [58%] and dysgeusia [50%]) were likely TRK inhibition-related. Median relative dose intensity was 90%; 14% (n = 66/472) of patients did not increase their initial QD dose to BID (mostly due to CNS AEs). Rates of dizziness (median onset, 7 days) were similar in patients with/without baseline brain metastases. Dose modifications downgraded severity or resolved dizziness in 78% of patients; 58% of patients had pharmacologic intervention without dose modification. Dizziness was downgraded/resolved in 62% (n = 120/195) of patients who did not receive dose modification or pharmacologic intervention. Treatment-related cognitive impairment and weight gain occurred in 19% and 12% of patients, respectively. Treatment-emergent withdrawal pain occurred in 14% of patients (median resolution time, 2.1 weeks). Dose interruption and reduction from TRAEs occurred in 39% and 38% of patients, respectively; 10% reported later re-escalation back to 160 mg BID.

Conclusion

Many repotrectinib AEs, including neurological AEs secondary to TRK inhibition, were mitigated with appropriate management, including dose modification and/or pharmacologic intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsProtein Kinase InhibitorsPyrazolesPyrimidinesMacrocyclic CompoundsAdultAgedFemaleHumansMaleMiddle AgedProtein-Tyrosine KinasesTyrosine Kinase InhibitorsProto-Oncogene Proteins

Stichwörter der Autor:innen

NSCLCRepotrectinibTRIDENT-1clinical managementsafety management

Substanzen

Protein Kinase InhibitorsProtein-Tyrosine KinasesPyrazolesPyrimidinesrepotrectinibROS1 protein, humanTyrosine Kinase InhibitorsMacrocyclic CompoundsProto-Oncogene Proteins

Autor:innen und Institutionen

  • Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, United States.
  • Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Anschutz Medical Campus, University of Colorado, Aurora, CO, United States.
  • School of Medicine, University of California, Irvine, Orange, CA, United States.
  • Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif, France.
  • Peter MacCallum Cancer Centre, Melbourne, Australia.

ORCID-Profile: Alexander Drilon, Misako Nagasaka, Benjamin Besse, Koichi Goto, Sanjay Popat, Adrianus Johannes de Langen, Andrew L Lin

Förderung

  • NCI NIH HHS
  • National Cancer Institute/National Institutes of Health
  • Nonna's Garden
  • Bristol Myers Squibb Company
  • Turning Point Therapeutics
  • TRIDENT-1 ClinicalTrials.gov
  • Nonna’s Garden

Zitieren

APA

Drilon, A., Cho, B. C., Camidge, D. R., Nagasaka, M., Besse, B., Solomon, B., Goto, K., Wolf, J., Popat, S., Felip, E., Yang, N., de Langen, A. J., Lu, S., Velcheti, V., Lin, A. L., Calvet, C. Y., Li, L., Tschaika, M., Afsar, S., …, & Lin, J. J. (2026). Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis. The Oncologist. https://doi.org/10.1093/oncolo/oyag137

Vancouver

Drilon A, Cho BC, Camidge DR, Nagasaka M, Besse B, Solomon B, et al. Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis. The Oncologist. 2026. doi:10.1093/oncolo/oyag137

BibTeX
@article{Drilon2026,
  author = {Drilon, Alexander and Cho, Byoung Chul and Camidge, D Ross and Nagasaka, Misako and Besse, Benjamin and Solomon, Benjamin and Goto, Koichi and Wolf, Jürgen and Popat, Sanjay and Felip, Enriqueta and Yang, Nong and de Langen, Adrianus Johannes and Lu, Shun and Velcheti, Vamsidhar and Lin, Andrew L and Calvet, Christophe Y and Li, Li and Tschaika, Marina and Afsar, Salman and Yang, Haisu and Lin, Jessica J},
  title = {Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag137}
}
Kostenlos starten →